Anti-Daratumumab ELISA Kit (AB691018)

Fiche technique Partager le produit Copier les informations

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	AB691018
Description	_x005F_x000d_ _x005F_x000d_ _x005F_x000d_ _x005F_x000d_ _x005F_x000d_ _x005F_x000d_ Anti-Daratumumab ELISA Kit (AB691018) — Quantitative sandwich ELISA for Anti-Daratumumab. Sample: Plasma, Serum. Range: 156.25 - 10, 000 ng/mL. _x005F_x000d_ _x005F_x000d_ _x005F_x000d_ Highlights _x005F_x000d_ _x005F_x000d_ _x005F_x000d_ ●Sandwich Format — High specificity, reliable quantification. _x005F_x000d_ ●Ready-to-Use — Complete kit with pre-coated plates included. _x005F_x000d_ _x005F_x000d_ _x005F_x000d_
Type d'échantillon	Plasma, Serum
Plage	156.25 - 10, 000 ng/mL
Numéro d'accès	P28907
Applications	ELISA
Méthode de détection	Colorimetric
Type de test	Quantitative
Retraitement	80-120%
Expédition	2-8 ℃
Stabilité et stockage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Spécifications	Daratumumab _x005F_x005F_x000d_
Noms alternatifs	945721-28-8
Contexte	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (Daratumumab) is a ~34 kDa protein. Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands. Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+). Has cADPR hydrolase activity. _x005F_x005F_x000d_ _x005F_x005F_x000d_ 1. Tohgo, A. et al. (1994) The Journal of biological chemistry 269, 28555-7. PMID: 7961800 _x005F_x005F_x000d_ _x005F_x005F_x000d_ 2. Takasawa, S. et al. (1993) The Journal of biological chemistry 268, 26052-4. PMID: 8253715 _x005F_x005F_x000d_ _x005F_x005F_x000d_ 3. Moreschi, I. et al. (2006) Biochemical and biophysical research communications 345, 573-80. PMID: 16690024 _x005F_x005F_x000d_ _x005F_x005F_x000d_ 4. Deaglio, S. et al. (1998) Journal of immunology (Baltimore, Md. : 1950) 160, 395-402. PMID: 9551996 _x005F_x005F_x000d_ _x005F_x005F_x000d_ 5. Frasca, L. et al. (2006) Blood 107, 2392-9. PMID: 16293598 _x005F_x005F_x000d_ _x005F_x005F_x000d_ 6. Deaglio, S. et al. (2001) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15, 580-2. PMID: 11259373 _x005F_x005F_x000d_
Note	For Research Use Only.